<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Linders DGJ</submitter><funding>Foundation for the National Institutes of Health</funding><funding>NCI NIH HHS</funding><pagination>58-73</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9971096</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>The majority of breast cancer patients is treated with breast-conserving surgery (BCS) combined with adjuvant radiation therapy. Up to 40% of patients has a tumor-positive resection margin after BCS, which necessitates re-resection or additional boost radiation. Cathepsin-targeted near-infrared fluorescence imaging during BCS could be used to detect residual cancer in the surgical cavity and guide additional resection, thereby preventing tumor-positive resection margins and associated mutilating treatments. The cysteine cathepsins are a family of proteases that play a major role in normal cellular physiology and neoplastic transformation. In breast cancer, the increased enzymatic activity and aberrant localization of many of the cysteine cathepsins drive tumor progression, proliferation, i</pubmed_abstract><journal>Molecular imaging and biology</journal><pubmed_title>Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery.</pubmed_title><pmcid>PMC9971096</pmcid><funding_grant_id>5R01CA246678</funding_grant_id><funding_grant_id>R01 CA246678</funding_grant_id><pubmed_authors>Bijlstra OD</pubmed_authors><pubmed_authors>Valentijn ARPM</pubmed_authors><pubmed_authors>Straight B</pubmed_authors><pubmed_authors>Hilling DE</pubmed_authors><pubmed_authors>Basilion JP</pubmed_authors><pubmed_authors>Vahrmeijer AL</pubmed_authors><pubmed_authors>Fallert LC</pubmed_authors><pubmed_authors>Burggraaf J</pubmed_authors><pubmed_authors>March TL</pubmed_authors><pubmed_authors>Linders DGJ</pubmed_authors><pubmed_authors>Walker E</pubmed_authors><pubmed_authors>Pool M</pubmed_authors><pubmed_authors>Kuppen PJK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery.</name><description>The majority of breast cancer patients is treated with breast-conserving surgery (BCS) combined with adjuvant radiation therapy. Up to 40% of patients has a tumor-positive resection margin after BCS, which necessitates re-resection or additional boost radiation. Cathepsin-targeted near-infrared fluorescence imaging during BCS could be used to detect residual cancer in the surgical cavity and guide additional resection, thereby preventing tumor-positive resection margins and associated mutilating treatments. The cysteine cathepsins are a family of proteases that play a major role in normal cellular physiology and neoplastic transformation. In breast cancer, the increased enzymatic activity and aberrant localization of many of the cysteine cathepsins drive tumor progression, proliferation, i</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-19T02:43:19.549Z</modification><creation>2025-02-19T04:54:23.698Z</creation></dates><accession>S-EPMC9971096</accession><cross_references><pubmed>36002710</pubmed><doi>10.1007/s11307-022-01768-4</doi></cross_references></HashMap>